Trinity Capital Inc. Commits $35 Million in Equipment Financing to ApiJect
Trinity Capital Inc. (NASDAQ: TRIN) has committed $35 million in equipment financing to ApiJect Systems, Corp, a medical technology company focused on prefilled, single-dose injection devices. ApiJect, based in Stamford, CT, designs rapidly scalable, cost-efficient drug delivery systems for pharmaceutical companies. The financing will enable ApiJect to maximize the value of their hard assets, scale operations, and fund growth initiatives.
ApiJect aims to make injectable medicines and vaccines safer and more accessible worldwide. The company plans to expand its manufacturing capacity in the U.S., file for regulatory approval for its initial device in the coming months, and partner with more pharmaceutical companies interested in using their injection technology.
Trinity Capital Inc. (NASDAQ: TRIN) ha impegnato 35 milioni di dollari per il finanziamento di attrezzature a ApiJect Systems, Corp, un'azienda di tecnologia medica focalizzata su dispositivi per iniezione pre-riempiti e monodose. ApiJect, con sede a Stamford, CT, progetta sistemi di somministrazione di farmaci scalabili rapidamente e a costi contenuti per le aziende farmaceutiche. Il finanziamento consentirà ad ApiJect di massimizzare il valore dei propri beni tangibili, espandere le operazioni e finanziare iniziative di crescita.
ApiJect si propone di rendere i farmaci iniettabili e i vaccini più sicuri e accessibili in tutto il mondo. L'azienda prevede di ampliare la sua capacità produttiva negli Stati Uniti, di presentare domanda per l'approvazione normativa del suo dispositivo iniziale nei prossimi mesi e di collaborare con altre aziende farmaceutiche interessate ad utilizzare la loro tecnologia di iniezione.
Trinity Capital Inc. (NASDAQ: TRIN) se ha comprometido a financiar 35 millones de dólares en equipo a ApiJect Systems, Corp, una empresa de tecnología médica centrada en dispositivos de inyección de dosis única precargados. ApiJect, con sede en Stamford, CT, diseña sistemas de entrega de medicamentos escalables de manera rápida y rentable para las compañías farmacéuticas. El financiamiento permitirá a ApiJect maximizar el valor de sus activos físicos, escalar las operaciones y financiar iniciativas de crecimiento.
ApiJect tiene como objetivo hacer que los medicamentos inyectables y las vacunas sean más seguros y accesibles en todo el mundo. La compañía planea expandir su capacidad de fabricación en EE. UU., presentar solicitudes de aprobación regulatoria para su dispositivo inicial en los próximos meses y asociarse con más empresas farmacéuticas interesadas en utilizar su tecnología de inyección.
트리니티 캐피탈 Inc. (NASDAQ: TRIN)은 ApiJect Systems, Corp에 3,500만 달러의 장비 금융을 약속했습니다. ApiJect는 프리필된 단일 용량 주사 장치에 중점을 두고 있는 의료 기술 회사입니다. 코네티컷주 스탬포드에 본사를 두고 있는 ApiJect는 제약 회사를 위한 신속하게 확장 가능한 비용 효율적인 약물 전달 시스템을 설계합니다. 이번 자금 조달은 ApiJect가 고정 자산의 가치를 극대화하고, 운영을 확장하며, 성장 이니셔티브를 지원할 수 있도록 합니다.
ApiJect는 전 세계적으로 주사 가능한 의약품과 백신을 더 안전하고 접근 가능하게 만들고자 합니다. 회사는 미국에서 제조 용량을 확장하고, 향후 몇 달 안에 초기 장치에 대한 규제 승인을 신청하며, 자사의 주사 기술을 사용하려는 더 많은 제약사와 파트너 관계를 맺을 계획입니다.
Trinity Capital Inc. (NASDAQ: TRIN) a engagé 35 millions de dollars dans le financement d'équipement pour ApiJect Systems, Corp, une entreprise de technologie médicale axée sur les dispositifs d'injection pré-remplis et à dose unique. ApiJect, basée à Stamford, CT, conçoit des systèmes de distribution de médicaments rapidement évolutifs et rentables pour les entreprises pharmaceutiques. Ce financement permettra à ApiJect de maximiser la valeur de ses actifs tangibles, d'élargir ses opérations et de financer des initiatives de croissance.
ApiJect vise à rendre les médicaments et les vaccins injectables plus sûrs et plus accessibles dans le monde entier. L'entreprise prévoit d'augmenter sa capacité de production aux États-Unis, de demander l'approbation réglementaire pour son dispositif initial dans les mois à venir et de collaborer avec davantage d'entreprises pharmaceutiques intéressées par l'utilisation de sa technologie d'injection.
Trinity Capital Inc. (NASDAQ: TRIN) hat 35 Millionen Dollar für die Ausrüstungsfinanzierung an ApiJect Systems, Corp zugesagt, ein Medizintechnologieunternehmen, das sich auf vorgefüllte Einzeldosis-Injektionsgeräte konzentriert. ApiJect mit Sitz in Stamford, CT, entwickelt schnell skalierbare, kosteneffiziente Arzneimittelabgabesysteme für Pharmaunternehmen. Die Finanzierung ermöglicht es ApiJect, den Wert ihrer Sachanlagen zu maximieren, die Betriebsabläufe zu skalieren und Wachstumsinitiativen zu finanzieren.
ApiJect hat sich zum Ziel gesetzt, injizierbare Medikamente und Impfstoffe weltweit sicherer und zugänglicher zu machen. Das Unternehmen plant, seine Produktionskapazitäten in den USA auszubauen, in den kommenden Monaten eine regulatorische Genehmigung für sein erstes Gerät zu beantragen und mit weiteren Pharmaunternehmen zusammenzuarbeiten, die an der Nutzung ihrer Injektionstechnologie interessiert sind.
- Commitment of $35 million in equipment financing to ApiJect
- Potential for expanded manufacturing capacity in the U.S.
- Upcoming regulatory approval filing for initial device
- Growing list of potential pharmaceutical company partnerships
- None.
Insights
Trinity Capital's
The financing structure, leveraging ApiJect's hard assets, is a prudent approach that minimizes risk for Trinity while providing ApiJect with necessary capital for expansion. This arrangement could lead to improved financial metrics for Trinity, potentially boosting investor confidence. However, the success of this investment hinges on ApiJect's ability to secure regulatory approvals and pharmaceutical partnerships, which introduces some element of risk.
ApiJect's focus on prefilled, single-dose injection devices represents a significant innovation in drug delivery systems. Their technology has the potential to revolutionize vaccine and medicine distribution, particularly in areas with healthcare infrastructure. The emphasis on rapid scalability and cost-efficiency addresses critical challenges in global health.
The upcoming regulatory filing for ApiJect's initial device is a crucial milestone. If approved, it could lead to widespread adoption, given the growing demand for efficient drug delivery systems. The partnership with Trinity Capital provides the necessary financial backing to accelerate this process. However, success will ultimately depend on the clinical efficacy and cost-effectiveness of ApiJect's technology compared to existing solutions.
The partnership between Trinity Capital and ApiJect taps into the growing market for innovative drug delivery systems. With increasing focus on global health equity and efficient vaccine distribution, ApiJect's technology is well-positioned to capture significant market share. The company's ability to attract
ApiJect's strategy of partnering with pharmaceutical companies for device design and manufacturing is a smart approach to market penetration. This model could lead to rapid adoption if successful. However, the market for drug delivery systems is competitive, with established players. ApiJect's success will depend on its ability to demonstrate clear advantages in terms of cost, efficiency and scalability over existing solutions.
Based in
"We are proud to support ApiJect on their mission to make injectable medicines and vaccines safer and accessible to everyone," said Melana Ferguson, Director, Equipment Finance at Trinity. "We look forward to working with their talented leadership team to accelerate the company's growth."
The new facility from Trinity will allow ApiJect to maximize the value of their hard assets to continue to scale operations and fund growth initiatives.
"We built the ApiJect injection platform to deliver an affordable prefilled option for most, if not all, injection medicines supported by a high volume manufacturing process and compact supply chain," said Jay Walker, Co-Founder, Executive Chairman, and CEO of ApiJect. "With Trinity's partnership, we are well positioned to expand our manufacturing capacity here in the
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN), an internally managed business development company, is a leading provider of diversified financial solutions to growth-stage companies with institutional equity investors. Trinity Capital's investment objective is to generate current income and, to a lesser extent, capital appreciation through investments, including term loans and equipment financings and equity-related investments. Trinity Capital believes it is one of only a select group of specialty lenders that has the depth of knowledge, experience and track record in lending to growth stage companies. For more information, please visit the Company's website at www.trinitycap.com.
About ApiJect Systems
ApiJect Systems, Corp. is a public-benefit medical technology company working to bring prefilled, single-dose injections to more people in every market. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own ApiJect-licensed Blow-Fill-Seal packaging lines or at one of our world-class manufacturing partners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-commits-35-million-in-equipment-financing-to-apiject-302230972.html
SOURCE Trinity Capital Inc.
FAQ
What is the amount of equipment financing Trinity Capital (TRIN) committed to ApiJect?
How will ApiJect use the financing from Trinity Capital (TRIN)?
What is ApiJect's main focus as a medical technology company?
When does ApiJect plan to file for regulatory approval for its initial device?
